title: Vinblastine and erythromycin: an unrecognized serious drug interaction.
abstract: Vinblastine and erythromycin are among the most commonly used chemotherapeutic and antimicrobial agents, respectively. No interaction between the two has ever been reported. Towards the end of a phase I study of vinblastine plus oral cyclosporin (to reverse multidrug resistance), three patients also received erythromycin to raise their cyclosporin levels. All developed severe toxicity consistent with a much higher vinblastine dose than was actually given. This apparent potentiation of vinblastine toxicity has not been previously described.
authors: Division of Nephrology, Sunnybrook Health Science Centre, University of Toronto, Canada.
authors: S W
authors: SW
authors: Tobe
authors: L L
authors: LL
authors: Siu
authors: S A
authors: SA
authors: Jamal
authors: K L
authors: KL
authors: Skorecki
authors: G F
authors: GF
authors: Murphy
authors: E
authors: E
authors: Warner
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D003248:Constipation / Q000139:chemically induced; D016572:Cyclosporine / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D014747:Vinblastine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014747:Vinblastine; D004917:Erythromycin; D016572:Cyclosporine